Heron Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Heron Therapeutics (NASDAQ:HRTX) reported Q4 earnings with an EPS of $-0.07, beating estimates by 56%, and revenue up $4.21M YOY. The company has a history of beating EPS estimates, leading to significant share price increases.
March 12, 2024 | 8:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Heron Therapeutics reported a significant beat on Q4 earnings and a year-over-year revenue increase, continuing its trend of surpassing EPS estimates.
Heron Therapeutics' consistent history of beating EPS estimates and the significant beat this quarter suggest a positive short-term impact on its stock price. The company's past performance indicates that beating EPS estimates can lead to substantial share price increases the following day.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100